Sagimet Biosciences Partners with Ascletis for Acne Therapy
Sagimet Biosciences Inc. (NASDAQ: SGMT), a clinical-stage biopharmaceutical innovator, has announced exciting developments! The company specializes in creating new therapies that target metabolic and fibrotic pathways to address various health conditions. Recently, their partner Ascletis Pharma Inc. received acceptance from China’s National Medical Products Administration (NMPA) for a New Drug Application (NDA) concerning denifanstat, a promising treatment for moderate to severe acne.
What is Denifanstat?
Denifanstat is an oral small molecule fatty acid synthase (FASN) inhibitor that Ascletis has been developing specifically for the acne market in China under the project name ASC40. This innovative treatment has shown significant effectiveness in clinical trials, addressing acne vulgaris while also being well-tolerated by patients. Sagimet is concurrently advancing denifanstat as a treatment for metabolic dysfunction associated with steatohepatitis (MASH) worldwide.
Clinical Trial Success
The NDA submitted by Ascletis is built upon successful data from their Phase 3 clinical trial, which assessed denifanstat's efficacy in treating moderate to severe acne. Impressively, the results indicated that the treatment successfully met all its primary and secondary endpoints, demonstrating both its effectiveness and safety profile.
About Sagimet Biosciences
Sagimet is focused on pioneering treatments through innovative research. Their platform includes developing FASN inhibitors, which are aimed at correcting metabolic and fibrotic issues often caused by the excessive production of palmitate, a fatty acid. Denifanstat has not only been effective in clinical trials for acne but has also shown promise in treating metabolic disorders in other studies.
Future Directions for Sagimet
Sagimet is actively working on future opportunities for denifanstat and other compounds. A combination therapy involving denifanstat and resmetirom is under investigation in a Phase 1 PK clinical trial and specifically targets cirrhotic patients with F4-stage MASH. Additionally, TVB-3567, another oral FASN inhibitor aimed at treating acne, is currently in first-in-human trials, which shows Sagimet's commitment to expanding its portfolio and addressing critical health issues.
Investor and Media Contacts
Sagimet Biosciences continues to enhance its communication with investors and the media. For those seeking further details about the company's developments, Joyce Allaire from LifeSci Advisors is the investor contact.
Contact Information
To reach Joyce Allaire, email: JAllaire@LifeSciAdvisors.com.
The media contact is Michael Fitzhugh, who may be reached via email at mfitzhugh@lifescicomms.com.
Frequently Asked Questions
What is denifanstat?
Denifanstat is an oral medication developed by Sagimet and its partner Ascletis for the treatment of moderate to severe acne.
Who is collaborating with Sagimet Biosciences?
Ascletis Pharma Inc. is the license partner working with Sagimet on denifanstat.
What are the potential applications of denifanstat?
Aside from treating acne, denifanstat is also being studied for metabolic dysfunction associated with steatohepatitis (MASH).
What is the status of clinical trials for denifanstat?
Denifanstat has met all primary and secondary endpoints in its multi-phase clinical trials and has received regulatory acceptance for further development.
How can investors learn more about Sagimet's activities?
Investors can contact Joyce Allaire at LifeSci Advisors for more information about Sagimet’s developments.